on MAUNA KEA TECHNOLOGIES (EPA:MKEA)
Mauna Kea Technologies is expanding into the Middle East
Mauna Kea Technologies, a specialist in endomicroscopy, announces a significant milestone in its development. It has obtained regulatory approvals for its Cellvizio device in the United Arab Emirates and Turkey. This advancement enables the commercial launch of CellTolerance, dedicated to the analysis of gut-brain interaction disorders, in a region where 27% of the population is affected by irritable bowel syndrome.
The first sales of CellTolerance have already been finalized in the United Arab Emirates. The Middle East represents a strategic market due to the high prevalence of bowel disorders. Mauna Kea's strategy is based on a patient-pay-as-you-go model, well-suited to this high-potential region.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MAUNA KEA TECHNOLOGIES news